longevity

According to market news, Changshou Medicine and the RAIN token asset pool Enlivex announced that they have obtained $21 million in debt financing from the New York institutional fund The Lind Partners.The company stated that it will continue to implement its predictive market token asset pool strategy, adding approximately 3 billion RAIN tokens, which will be used to support the company's operational plans. Enlivex is a Nasdaq-listed company that is developing therapies for joint diseases such as osteoarthritis, while holding a large position in RAIN as part of the RAIN digital asset pool. RAIN is a decentralized predictive market protocol token deployed on the Arbitrum network, which determines outcomes through AI and employs a buyback and burn mechanism. Enlivex's stock price is currently around $1.05, down about 5% for the day.

ChainCatcher news, Coinbase CEO co-founded longevity research company NewLimit forwarded a message from its co-founder Jacob Kimmel stating that NewLimit has recently secured an additional $45 million in funding, with investors including Lilly Ventures, Duke University, S32, Abstract, and participation from existing shareholders such as Kleiner Perkins, Dimension, Human Capital, and Boost VC.This round of financing is based on technological breakthroughs in its young liver function restoration project, with plans to initiate clinical research in the coming years.

ChainCatcher news, according to Bloomberg, BitMEX co-founder Arthur Hayes is shifting his investment focus to the field of human longevity. He has recently made a significant investment in a stem cell company that has clinics in Mexico and Bangkok, and has joined its board of directors.Over the past year, he has regularly traveled to receive intravenous infusion treatments, stating that he "hopes to extend his life as healthily as possible." Although the company name has not been disclosed due to rebranding, he emphasized: this is the trend of the future—more and more countries are relaxing regulations on the use of stem cells.

ChainCatcher message, Ethereum co-founder Vitalik Buterin stated in a post on Farcaster, "The cultural differences between the United States and China are about four times the cultural differences between two generations that are roughly 30 years apart.But I predict that as technological advancements accelerate and the world becomes increasingly interconnected, this ratio will reverse, leading to unexpected consequences and impacts. (For example: longevity technology itself may become a form of 'cultural preservation.')"

ChainCatcher news, the decentralized longevity research organization VitaDAO announced a collaboration with biologist Vera Gorbunova to establish a biotechnology company, Matrix Biosciences, focused on longevity research. Matrix Biosciences aims to identify the best candidate drugs for treating cancer and age-related diseases using its cutting-edge research. VitaDAO will provide an initial funding of $300,000, which will be raised through IP tokenization in early 2024.According to the crypto data platform RootData, VitaDAO announced in January this year that it had completed a $4.08 million funding round, with participation from Spaceship DAO, Beaker DAO, Shine Capital, L1 Digital, Balaji Srinivasan, and others.

ChainCatcher news, the decentralized longevity science research organization VitaDAO announced the completion of a $4.1 million token financing, with participation from Pfizer's venture capital arm, Shine Capital, L1 Digital, and Balaji Srinivasan. This round of financing concluded this month, marking Pfizer's first investment in the web3 space. In September 2022, Pfizer announced a commitment of $500,000 to VitaDAO.It is reported that VitaDAO is part of a nascent movement known as decentralized science (DeSci). DeSci aims to replace the current scientific ecosystem that relies on centralized research and funding institutions by crowdfunding and decentralizing ownership to raise funds for research. The projects funded by VitaDAO primarily focus on longevity and the aging process, currently supporting Turn Biotechnologies, a Stanford University spin-off producing mRNA drugs, as well as a study at the University of Copenhagen on understanding the effects of drugs on the aging process. (The Block)

Chain Catcher news, the public chain Aptos announced the participation status of Incentive Testnet 3 (AIT3), which completed over 800 million transactions in less than 2 weeks, achieving over 4000 TPS.In terms of testing rewards, a 50% increase in rewards has been added for participants, raising the maximum token reward from 800 to 1200 tokens. Token rewards will be assessed in phases, with those meeting ≥ 50% staking rewards receiving 800 tokens, and those meeting ≥ 9% staking rewards or having zero governance votes receiving 500 tokens.Additionally, Aptos stated that the recently launched testnet NFT series APTOS: ZERO marks the launch of its Longevity Testnet, indicating confidence in the state of its software and deployment architecture. The Longevity Testnet NFTs will be retained for a long time, unlike the previous weekly resets.Aptos plans to no longer make significant changes to Move, transactions, and APIs, and there will be no more data resets, as effective partnerships can be established between DApps and other entities. Aptos will continue to introduce changes to the devnet weekly and perform resets weekly. (Source link)